Mylan points finger at FDA for failure to win nods on Advair, Copaxone copies
admin 9th August 2017 Uncategorised 0The FDA is speeding up generics approvals. It’s just not speeding up the ones Mylan needs. Wednesday, the knockoffs giant said it would remove copies of big guns Copaxone from Teva and Advair from GlaxoSmithKline from its 2017 guidance, pushing them into 2018 instead.
More: Mylan points finger at FDA for failure to win nods on Advair, Copaxone copies
Source: fierce